Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
Identifieur interne : 001257 ( Istex/Corpus ); précédent : 001256; suivant : 001258Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
Auteurs : Korczyn ; David J. Brooks ; Ehrout R. Brunt ; Warner H. Poewe ; Olivier Rascol ; Fabrizzio StocchiSource :
- Movement Disorders [ 0885-3185 ] ; 1998-01.
English descriptors
- KwdEn :
Abstract
We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.
Url:
DOI: 10.1002/mds.870130112
Links to Exploration step
ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name><affiliation><mods:affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Groningen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name><affiliation><mods:affiliation>Department of Neurological Science, University la Sapienza, Rome, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130112</idno><idno type="url">https://api.istex.fr/document/9B528618A0950D500A47E6F3C3B5917D43BDAB73/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001257</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name><affiliation><mods:affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Groningen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name><affiliation><mods:affiliation>Department of Neurological Science, University la Sapienza, Rome, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-01">1998-01</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="46">46</biblScope><biblScope unit="page" to="51">51</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9B528618A0950D500A47E6F3C3B5917D43BDAB73</idno><idno type="DOI">10.1002/mds.870130112</idno><idno type="ArticleID">MDS870130112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bromocriptine</term><term>Dopamine agonist</term><term>Double‐blind, controlled study</term><term>Early Parkinson's disease</term><term>Ropinirole</term><term>Selegiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Prof. Korczyn</name><affiliations><json:string>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>David J. Brooks</name><affiliations><json:string>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</json:string></affiliations></json:item><json:item><name>Ehrout R. Brunt</name><affiliations><json:string>Department of Neurology, University Hospital, Groningen, The Netherlands</json:string></affiliations></json:item><json:item><name>Warner H. Poewe</name><affiliations><json:string>Department of Neurology, University of Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Olivier Rascol</name><affiliations><json:string>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</json:string></affiliations></json:item><json:item><name>Fabrizzio Stocchi</name><affiliations><json:string>Department of Neurological Science, University la Sapienza, Rome, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Bromocriptine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Double‐blind, controlled study</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Early Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Ropinirole</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Selegiline</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</abstract><qualityIndicators><score>6.465</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1534</abstractCharCount><pdfWordCount>3849</pdfWordCount><pdfCharCount>25203</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>218</abstractWordCount></qualityIndicators><title>Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><genre><json:string>Serial article</json:string></genre><host><volume>13</volume><pages><total>6</total><last>51</last><first>46</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1002/mds.870130112</json:string></doi><id>9B528618A0950D500A47E6F3C3B5917D43BDAB73</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9B528618A0950D500A47E6F3C3B5917D43BDAB73/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9B528618A0950D500A47E6F3C3B5917D43BDAB73/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9B528618A0950D500A47E6F3C3B5917D43BDAB73/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1998</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><author><persName><surname>Korczyn</surname><roleName type="degree">Prof.</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv 64239, Israel</p></note><affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">David J.</forename><surname>Brooks</surname></persName><affiliation>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</affiliation></author><author><persName><forename type="first">Ehrout R.</forename><surname>Brunt</surname></persName><affiliation>Department of Neurology, University Hospital, Groningen, The Netherlands</affiliation></author><author><persName><forename type="first">Warner H.</forename><surname>Poewe</surname></persName><affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><affiliation>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</affiliation></author><author><persName><forename type="first">Fabrizzio</forename><surname>Stocchi</surname></persName><affiliation>Department of Neurological Science, University la Sapienza, Rome, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-01"></date><biblScope unit="vol">13</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="46">46</biblScope><biblScope unit="page" to="51">51</biblScope></imprint></monogr><idno type="istex">9B528618A0950D500A47E6F3C3B5917D43BDAB73</idno><idno type="DOI">10.1002/mds.870130112</idno><idno type="ArticleID">MDS870130112</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Bromocriptine</term></item><item><term>Dopamine agonist</term></item><item><term>Double‐blind, controlled study</term></item><item><term>Early Parkinson's disease</term></item><item><term>Ropinirole</term></item><item><term>Selegiline</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1996-10-28">Received</change><change when="1997-04-25">Registration</change><change when="1998-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9B528618A0950D500A47E6F3C3B5917D43BDAB73/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v13:1</doi><numberingGroup><numbering type="journalVolume" number="13">13</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1998-01">January 1998</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="12" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870130112</doi><idGroup><id type="unit" value="MDS870130112"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1998 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1996-10-28"></event><event type="manuscriptRevised" date="1997-04-21"></event><event type="manuscriptAccepted" date="1997-04-25"></event><event type="firstOnline" date="2004-11-04"></event><event type="publishedOnlineFinalForm" date="2004-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">46</numbering><numbering type="pageLast">51</numbering></numberingGroup><correspondenceTo>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv 64239, Israel</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870130112.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="28"></count></countGroup><titleGroup><title type="main" xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><title type="short" xml:lang="en">ROPINIROLE VERSUS BROMOCRIPTINE IN EARLY PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Prof.</honorifics><givenNames>Amos D.</givenNames><familyName>Korczyn</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>David J.</givenNames><familyName>Brooks</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Ehrout R.</givenNames><familyName>Brunt</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Warner H.</givenNames><familyName>Poewe</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Fabrizzio</givenNames><familyName>Stocchi</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IL" type="organization"><unparsedAffiliation>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="NL" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital, Groningen, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurological Science, University la Sapienza, Rome, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Bromocriptine</keyword><keyword xml:id="kwd2">Dopamine agonist</keyword><keyword xml:id="kwd3">Double‐blind, controlled study</keyword><keyword xml:id="kwd4">Early Parkinson's disease</keyword><keyword xml:id="kwd5">Ropinirole</keyword><keyword xml:id="kwd6">Selegiline</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>ROPINIROLE VERSUS BROMOCRIPTINE IN EARLY PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Prof.</namePart><namePart type="family">Korczyn</namePart><affiliation>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation><description>Correspondence: Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv 64239, Israel</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David J.</namePart><namePart type="family">Brooks</namePart><affiliation>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ehrout R.</namePart><namePart type="family">Brunt</namePart><affiliation>Department of Neurology, University Hospital, Groningen, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Warner H.</namePart><namePart type="family">Poewe</namePart><affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><affiliation>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrizzio</namePart><namePart type="family">Stocchi</namePart><affiliation>Department of Neurological Science, University la Sapienza, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1998-01</dateIssued><dateCaptured encoding="w3cdtf">1996-10-28</dateCaptured><dateValid encoding="w3cdtf">1997-04-25</dateValid><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">28</extent></physicalDescription><abstract lang="en">We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</abstract><subject lang="en"><genre>Keywords</genre><topic>Bromocriptine</topic><topic>Dopamine agonist</topic><topic>Double‐blind, controlled study</topic><topic>Early Parkinson's disease</topic><topic>Ropinirole</topic><topic>Selegiline</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>46</start><end>51</end><total>6</total></extent></part></relatedItem><identifier type="istex">9B528618A0950D500A47E6F3C3B5917D43BDAB73</identifier><identifier type="DOI">10.1002/mds.870130112</identifier><identifier type="ArticleID">MDS870130112</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1998 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001257 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001257 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73
|texte= Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
}}
| This area was generated with Dilib version V0.6.23. |  |